Spark Therapeutics commercially launched the first gene therapy for a genetic disease in the US and established human proof-of-concept for Spark’s gene therapy treatments of retina and liver diseases. In the four years since inception, Spark has secured more than $1 billion in capital and built a company of more than 320 colleagues. In 2012, Novocure introduced its Optune® device which uses electrical fields (Tumor Treating Fields) to disrupt cell division and fight cancer. Optune® is FDA approved for treatment of the most aggressive form of brain cancer and glioblastoma, and Novocure is conducting clinical trials on a variety of other cancers. In this panel, the CEO of Spark Therapeutics and the General Counsel of Novocure will discuss the challenges of bringing a ground breaking technology to market.